Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)
Others
Ratios

Contineum Therapeutics (CTNM) Non Operating Income: 2023-2024

Historic Non Operating Income for Contineum Therapeutics (CTNM) over the last 2 years, with Dec 2024 value amounting to $2.5 million.

  • Contineum Therapeutics' Non Operating Income rose 42.15% to $2.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $8.6 million, marking a year-over-year increase of 21.77%. This contributed to the annual value of $8.6 million for FY2024, which is 21.75% up from last year.
  • According to the latest figures from Q4 2024, Contineum Therapeutics' Non Operating Income is $2.5 million, which was down 8.31% from $2.7 million recorded in Q3 2024.
  • In the past 5 years, Contineum Therapeutics' Non Operating Income ranged from a high of $3.4 million in Q2 2023 and a low of $291,000 during Q1 2023.
  • For the 2-year period, Contineum Therapeutics' Non Operating Income averaged around $2.0 million, with its median value being $1.8 million (2023).
  • Over the last 5 years, Contineum Therapeutics' Non Operating Income had its largest YoY gain of 419.93% in 2024, and its largest YoY loss of 42.34% in 2024.
  • Contineum Therapeutics' Non Operating Income (Quarterly) stood at $1.7 million in 2023, then soared by 42.15% to $2.5 million in 2024.
  • Its last three reported values are $2.5 million in Q4 2024, $2.7 million for Q3 2024, and $1.9 million during Q2 2024.